July 2025 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between June 19, 2025 through July 24, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24267 | USOR 24267 LYM 250 Phase 3 Zanubrutinib + Sonrotoclax or Placebo Q28D |
| 24057 | USOR 24057 HN 35 Phase 2 Double-Blind Zanzalintinib or Placebo + Pembrolizumab Q21D |
| MCCR SARC 08 |
SARC 08 Phase 1 Ziftomenib + Imatinib Q28D – 26AUG2024 |
| MCCR RM 1275 |
RM 1275 Phase 1 ENV-501 Q21D – v00 17SEP2024 |
| 24200 | USOR 24200 HN 40 Phase 3 PDS0101 + Pembrolizumab Q21D – v3.0 12NOV2024 USOR 24200 HN 40 Phase 3 Pembrolizumab Q21D – v3.0 12NOV2024 |
| 24208 | USOR 24208 BRE 449 Phase 2 Part 1 Safety Lead-in Pembrolizumab + HER3-DXd fb Pembrolizumab + Paclitaxel + Carboplatin Q21D
USOR 24208 BRE 449 Phase 2 Part 2 Arm A Pembrolizumab + HER3-DXd fb Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm B Pembrolizumab + Paclitaxel + Carboplatin fb Pembrolizumab + HER3-DXd Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm C Pembrolizumab + Paclitaxel + Carboplatin fb Pembrolizumab + Doxorubicin or Epirubicin + Cyclophosphamide Q21D USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Capecitabine (Cycle 9+) Q42D USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Doxorubicin or Epirubicin + Cyclophosphamide (Q2W) Q42D (Cycle 9+) USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Doxorubicin or Epirubicin + Cyclophosphamide (Q3W) Q42D (Cycle 9+) USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Olaparib (Cycle 9+) Q42D |
| 25023 | USOR 25023 MM 195 Phase 2 Arm A Consolidation and Maintenance 1 Elranatamab + Daratumumab Q28D (Cycles 1-15) – v3.0 02APR2025
USOR 25023 MM 195 Phase 2 Arm A Maintenance 2 Elranatamab Q28D (Cycles 16-27) – v3.0 02APR2025 USOR 25023 MM 195 Phase 2 Arm A1 Late Intensification Maintenance Daratumumab + Lenalidomide Q28D (Cycles 16-27) – v3.0 02APR2025 USOR 25023 MM 195 Phase 2 Arm B Maintenance 1 Daratumumab + Lenalidomide Q28D (Cycles 1-12) – v3.0 02APR2025 USOR 25023 MM 195 Phase 2 Arm B Maintenance 2 Lenalidomide Q28D (Cycles 13-24) – v3.0 02APR2025 USOR 25023 MM 195 Phase 2 Arm B1 Late Intensification and Maintenance Elranatamab + Daratumumab Q28D (Cycles 13-27) – v3.0 02APR2025 USOR 25023 MM 195 Phase 2 Conditioning + ASCT (Off-site documentation) – v3.0 02APR2025 |
| 24006 | USOR 24006 LUN 573 Phase 3 Arm 1 Dato-DXd + Rilvegostomig (AZD2936) Q21D – v2.0 07AUG2024
USOR 24006 LUN 573 Phase 3 Arm 2 Rilvegostomig (AZD2936) Q21D – v2.0 07AUG2024 USOR 24006 LUN 573 Phase 3 Arm 3 Carboplatin + Pemetrexed Q21D – v2.0 07AUG2024 USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin + Etoposide D1-3 Q28D – v2.0 07AUG2024 USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin + Pemetrexed Q21D – v2.0 07AUG2024 USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin D1 + Vinorelbine D1,8 Q21D – v2.0 07AUG2024 USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin D1 + Vinorelbine D1,8,15,22 Q28D – v2.0 07AUG2024 USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin D1,8 + Vinorelbine D1,8,15,22 Q28D – v2.0 07AUG2024 |
| 24165 | USOR 24165 RM 1187 Phase 1 Singleplex TCR-T Day 1
USOR 24165 RM 1187 Phase 1 Singleplex TCR-T Q29D USOR 24165 RM 1187 Phase 1 T-Plex TCR-T Q29D USOR 24165 RM 1187 Regimen A Lymphodepletion Cyclophosphamide + Fludarabine Q7D USOR 24165 RM 1187 Regimen B Lymphodepletion Cyclophosphamide + Fludarabine Q7D USOR 24165 RM 1187 Regimen C Lymphodepletion Cyclophosphamide + Fludarabine Q7D |
| 23302 | USOR 23302 BRE 431 Phase 3 Arm A MK-2870 Q84D – 15NOV2024
USOR 23302 BRE 431 Phase 3 Arm B MK-2870 + Pembrolizumab Q84D – 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Capecitabine Q84D – 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Liposomal Doxorubicin Q84D – 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Nab-Paclitaxel Q84D – 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Paclitaxel (80 mg/m2) Q84D – 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Paclitaxel (90 mg/m2) Q84D – 15NOV2024 |
| 24199 | USOR 24199 GI 390 Phase 2 Substudy 1 Stage 1 or 2 Telisotuzumab adizutecan + FOLFOX + Bevacizumab Q28D
USOR 24199 GI 390 Phase 2 Substudy 1 Stage 2 FOLFOX + Bevacizumab Q28D USOR 24199 GI 390 Phase 2 Substudy 2 Stage 1 or 2 Telisotuzumab adizutecan + Fluorouracil + Leucovorin + Panitumumab Q28D USOR 24199 GI 390 Phase 2 Substudy 2 Stage 2 FOLFOX + Panitumumab Q28D |
| 24217 | USOR 24217 MULTI 96 Phase Ib WTX-124 + Pembrolizumab Q42D 04OCT2024
USOR 24217 MULTI 96 Phase Ib WTX-124 Q28D 04OCT2024 |
| 24079 | USOR 24079 MM 193 Phase 3 (DRd) Daratumumab + Lenalidomide + Dexamethasone Q28D
USOR 24079 MM 193 Phase 3 (Tal-DR) Talquetamab + Daratumumab + Lenalidomide + Dexamethasone Q28D USOR 24079 MM 193 Phase 3 (Tec-DR) Teclistamab + Daratumumab + Lenalidomide + Dexamethasone Q28D |
| 24285 | USOR 24285 GI 403 Phase 3 Octreotide LAR Q28D – v00 09DEC2024
USOR 24285 GI 403 Phase 3 [177Lu] Lu-DOTA-TATE + Octreotide LAR Q56D – v00 09DEC2024 |
| 23041 | USOR 23041 MPN 21 Phase 3 Givinostat Q112D v7.0 19NOV2024
USOR 23041 MPN 21 Phase 3 Givinostat Q28D v7.0 19NOV2024 USOR 23041 MPN 21 Phase 3 Hydroxyurea Q28D v7.0 19NOV2024 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 22067 | N/A | N/A | N/A | Updated drug: Admin Prep |
| 22273 | N/A | N/A | N/A | Closed Arm |
| 23337 | N/A | N/A | N/A | Added Drug, Updated drug admin/prep |
| 24100 | Version 4.0, 30April12025 | N/A | N/A | Updated Drug, Admin Prep |
| 24112 | N/A | N/A | N/A | Updated drug instructions. |
| 24250 | N/A | N/A | N/A | Updated drug instructions. |
| 23297 | N/A | N/A | N/A | Updated drug, Admin/prep |
| 24171 | PA 3, 12 March 2025 | N/A | Regimen Comments: Prophylaxis, Observation |
Updated drug instructions |
| 24145 | PA 6.0, 18 Feb 2025 | N/A | N/A | Updated drug instructions, Updated Dose/Form |
| 24026 | PM V3; 30 Jan 2025 | N/A | N/A | Updated drug instructions |
| 23141 | PA 08: 01 April 2025 | N/A | Regimen Comments: Prophylaxis | N/A |
| 24070 | Memo, 07 April 2025 | N/A | N/A | Updated drug dose, updated drug name |
| 23129 | Version 5.0, 29APR2025 | N/A | N/A | Updated drug instructions |
| 24224 | N/A | N/A | N/A | Updated drug: Admin/prep |
| 24288 | V2.1, 09 April 2025 | N/A | N/A | Updated drug: Admin/prep |
| 23166 | PA V10.0, 12 MAY 2025 | N/A | N/A | Reference change |
| 22201 | N/A | N/A | N/A | Added Drug |
| 24089 | PA v5.0, 28 JAN 2025 | N/A | N/A | Updated drug instructions |
| 23340 | PA V3.0, 29 MAY 2025 | N/A | Regimen Comments: Administration | Updated drug instructions |
| 24030 | PA2; 11 DEC 2024 | N/A | Regimen Comments: Administration | N/A |
| 23309 | Amendment 7, 30APR2025 | N/A | Regiment comments; prophylaxis | Updated drug instructions |
| 23084 | PA v5.0: 28 Feb 2025 | N/A | Regimen comments: administration, prophylaxis | Updated drug instructions, admin prep, premedication |